TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Investing.com - Guggenheim has reiterated its Buy rating and $45.00 price target on Sionna Therapeutics (NASDAQ:SION) following the company’s second-quarter 2025 financial results. According to InvestingPro data, analysts maintain a Strong Buy consensus, with price targets ranging from $32 to $45, suggesting significant upside potential from current levels.
The research firm highlighted Sionna’s recent positive topline Phase I safety and pharmacokinetic data, noting the company plans to advance both of its NBD1 stabilizers (SION-719 and SION-451) into further clinical development after testing in over 200 healthy volunteers.
SION-719 will proceed as a Trikafta add-on study due to its greater potency at lower doses, while SION-451 will advance as a candidate for dual combination studies with either SION-109 or SION-2222/Galicaftor, given its higher exposure at higher doses.
Sionna has already begun its midazolam drug-drug interaction study and expects to initiate a Phase IIa Trikafta add-on study in the second half of 2025, while remaining on track to start a Phase I healthy volunteer dual combination study in the same period, with topline results expected by mid-2026.
The company reported approximately $337.3 million in cash, cash equivalents, and marketable securities, which it believes will fund operations into 2028, as it pursues what Guggenheim describes as potentially "revolutionary" first-in-class NBD1 stabilizers for cystic fibrosis treatment.
In other recent news, Sionna Therapeutics has made significant strides in its cystic fibrosis treatment efforts. The company presented promising preclinical data at the European Cystic Fibrosis Conference, showcasing a dual combination approach using NBD1 stabilizers and proprietary modulators to correct CFTR protein function in models. Following these developments, Stifel analysts have reiterated their Buy rating for Sionna Therapeutics, maintaining a price target of $32.00. This comes after the company’s phase 1 program for the SION-719 and SION-451 compounds showed no new safety concerns and achieved desired pharmacokinetic exposures. Sionna is now advancing these drugs to the next phase of clinical trials, with both compounds demonstrating tolerability and meeting pharmacokinetic targets in healthy volunteers. Additionally, the company announced the results of its Annual Meeting of Stockholders, where all proposed nominees for the board of directors were elected. These recent developments underscore Sionna’s ongoing commitment to advancing its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.